Alex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 16-11-2024
- Paid Up Capital ₹ 3.00 M
as on 16-11-2024
- Company Age 29 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.90 Cr
as on 16-11-2024
- Satisfied Charges ₹ 1.03 Cr
as on 16-11-2024
- Revenue 24.21%
(FY 2023)
- Profit 63.18%
(FY 2023)
- Ebitda 182.46%
(FY 2023)
- Net Worth 13.55%
(FY 2023)
- Total Assets 59.49%
(FY 2023)
About Alex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹1.90 Cr. The company has closed loans amounting to ₹1.03 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bikesh Dangi and Shaileshkumar Dangi serve as directors at the Company.
- CIN/LLPIN
U24231GJ1995PTC025568
- Company No.
025568
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alex Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bikesh Dangi  | Director | 18-Jul-1995 | Current |
| Shaileshkumar Dangi | Director | 01-Jun-2003 | Current |
Financial Performance of Alex Pharmaceuticals.
Alex Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 24.21% increase. The company also saw a substantial improvement in profitability, with a 63.18% increase in profit. The company's net worth Soared by an impressive increase of 13.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alex Pharmaceuticals?
In 2023, Alex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Mar 2022 | ₹1.30 Cr | Open |
Kalupur Commercial Co-Operative Bank Creation Date: 17 Nov 2008 | ₹3.00 M | Open |
The Kalupur Commercial Co. Op. Bank Ltd. Creation Date: 11 Jul 2001 | ₹3.00 M | Open |
How Many Employees Work at Alex Pharmaceuticals?
Unlock and access historical data on people associated with Alex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
